

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
 CIN: L24230MH1999PLC120720
 Tel: 91 22 2853 4444; Fax: 91 22 2662 3905, Website: www.wockhardt.com

PART I					(Rs. in Lakhs)
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2015					
	PARTICULARS	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR ENDED
		30/06/2015	31/03/2015	30/06/2014	31/03/2015
	(Refer Notes Below)	Unaudited	Audited (Refer Note 5)	Unaudited	Audited
1	Income from Operations				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	114,065	107,914	99,119	440,024
	(b) Other operating income	-	-	-	8,130
	Total Income from Operations (net)	114,065	107,914	99,119	448,154
2	Expenses				
	(a) Cost of materials consumed	23,583	20,338	21,285	78,398
	(b) Purchase of Stock-in-trade	19,844	15,965	19,995	75,451
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,544)	985	(2,359)	(5,101)
	(d) Employee benefits expenses	23,215	22,955	20,962	86,887
	(e) Depreciation and amortisation expenses	3,465	3,438	3,639	14,540
	(f) Other expenses	33,441	34,077	32,980	129,809
	Total Expenses	100,804	97,758	96,502	379,984
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	13,261	10,156	2,617	68,170
4	Other Income	2,330	1,268	823	8,655
4a	Exchange fluctuation (gain)/ loss	(1,546)	3,980	(578)	11,770
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4 ± 4a)	17,137	7,444	4,016	63,055
6	Finance Cost	1,694	1,430	1,502	5,521
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	15,443	6,014	2,514	57,534
8	Exceptional Items Profit / (Loss)	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	15,443	6,014	2,514	57,534
10	Tax Expenses	3,354	2,711	293	16,265
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	12,089	3,303	2,221	41,269
12	Extraordinary items (net of Tax expense of Rs. lakhs)	-	-	-	-
13	Net Profit / (Loss) for the period after taxes but before minority interest & share of profit / (loss) of associates (11 ± 12)	12,089	3,303	2,221	41,269
14	Share of Profit/(Loss) of Associate	64	-	-	-
15	Minority interest - Profit / (Loss)	733	(105)	226	778
16	Net Profit/(Loss) after taxes, minority interest & share of profit / (loss) of associates (13 ± 14 ± 15)	11,420	3,408	1,995	40,491
17	Paid-up Share Capital (Rs. 5/- each)	5,510	5,504	5,500	5,504
18	Reserve excluding Revaluation Reserve as per balance sheet	-	-	-	336,176
19.i	Earnings Per Share (before extraordinary items) (*Not Annualised)				
	(a) Basic (Rs.)	10.37*	3.10*	1.81*	36.81
	(b) Diluted (Rs.)	10.26*	3.06*	1.80*	36.39
19.ii	Earnings Per Share (after extraordinary items) (*Not Annualised)				
	(a) Basic (Rs.)	10.37*	3.10*	1.81*	36.81
	(b) Diluted (Rs.)	10.26*	3.06*	1.80*	36.39
PART II: SELECT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2015					
A)	Particulars of Shareholding				
1	Public Shareholding				
	-Number of Shares	28,075,661	27,943,161	27,871,988	27,943,161
	- Percentage of Shareholding	25.48%	25.39%	25.34%	25.39%
2	Promoters and promoter group shareholding				
	a) Pledged/ Encumbered				
	- Number of shares	Nil	Nil	Nil	Nil
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%
	-Percentage of shares (as a % of the total share capital of the Company)	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered				
	- Number of shares	81,985,382	81,985,382	81,985,382	81,985,382
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	-Percentage of shares (as a % of the total share capital of the Company)	74.39%	74.48%	74.53%	74.48%
B)	Investors Complaints	3 MONTHS ENDED 30/06/2015			
	Pending at the beginning of the Quarter	Nil			
	Received during the quarter	Nil			
	Disposed of during the quarter	Nil			
	Remaining unresolved at the end of the quarter	Nil			



Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee at their meeting held on August 08, 2015 and approved by the Board of Directors at their meeting held on August 10, 2015.
- 2) During the quarter, the Company has allotted 132,500 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.
- 3) With effect from April 01, 2015, C P Pharmaceuticals Limited, UK, an erstwhile wholly owned subsidiary of Wockhardt UK Holdings Limited (a wholly owned subsidiary of the Company), has become wholly owned subsidiary of Wockhardt Bio AG, Switzerland, a subsidiary of the Company. During the quarter, Swiss Bio Sciences AG, an associate company of Wockhardt Bio AG, has been liquidated.
- 4) Effective April 1, 2015, the Group has exercised option given under paragraph 46A of Accounting Standard for The Effects of Changes in Foreign Exchange Rates (AS 11) prescribed under Section 133 of the Companies Act, 2013 whereby exchange differences arising on long term foreign currency monetary items relating to depreciable asset are adjusted in fixed assets and depreciated over the balance life of such assets and in other cases are accumulated in Foreign Currency Monetary item Translation Difference Account (FCMTDA) to be amortised over balance period of long term asset/liability. The balance outstanding/(debit) in FCMTDA as on June 30, 2015 is Rs. 825 lakhs.
- 5) Figures for the quarter ended March 31, 2015 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to the third quarter of the relevant financial year.
- 6) Key Financials on Standalone basis:

Particulars	(Rs in Lakhs)			
	QUARTER ENDED 30/06/2015	QUARTER ENDED 31/03/2015	QUARTER ENDED 30/06/2014	YEAR ENDED 31/3/2015
	Unaudited	Audited	Unaudited	Audited
Net Sales / Income from operations	51,470	49,078	48,544	188,655
Profit / (Loss) Before Tax	(2,512)	(2,820)	359	35,043
Profit / (Loss) After Tax	(2,498)	(1,406)	535	33,182

- 7) The Group is exclusively into Pharmaceutical business Segment.
- 8) Previous period figures have been recast / regrouped to conform to the current period's presentation.



FOR WOCKHARDT LIMITED

[Handwritten Signature]

H F KHORAKIWALA
CHAIRMAN

Vitznau, Switzerland
Date : August 10, 2015

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
 CIN:L24230MH1999PLC120720
 Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905 ;Website: www.wockhardt.com

(Rs. In Lakhs)					
PART I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2015					
	PARTICULARS (Refer notes below)	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR ENDED
		30/06/2015	31/03/2015	30/06/2014	31/03/2015
		Unaudited	Audited (Refer note 3)	Unaudited	Audited
1	Income from operations (a) Net sales/income from operations (net of excise duty) (b) Other operating income Total income from operations (net)	51,470 - 51,470	49,078 - 49,078	48,544 - 48,544	188,655 - 188,655
2	Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (e) Depreciation and amortisation expense (f) Other expenses Total expenses	11,269 13,196 (1,465) 11,479 2,507 16,792 53,778	11,556 11,138 (1,405) 10,813 2,517 17,448 52,067	11,759 9,311 (973) 9,675 2,470 15,629 47,871	45,201 40,214 (5,727) 40,962 10,293 65,554 196,497
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(2,308)	(2,989)	873	(7,842)
4	Other income	995	807	475	46,511
4a	Exchange fluctuation (gain) / loss	168	(1)	296	1,708
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4 ± 4a)	(1,481)	(2,181)	852	36,961
6	Finance costs	1,031	639	493	1,918
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	(2,512)	(2,820)	359	35,043
8	Exceptional items profit / (loss)	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	(2,512)	(2,820)	359	35,043
10	Tax expense	(14)	(1,414)	(176)	1,861
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	(2,498)	(1,406)	535	33,182
12	Extraordinary items (net of tax expense of Rs. lakhs)	-	-	-	-
13	Net Profit/ (Loss) for the period (11 ± 12)	(2,498)	(1,406)	535	33,182
14	Paid-up equity share capital (face value Rs. 5/- each)	5,510	5,504	5,500	5,504
15	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	101,650
16.i	Earnings per share (before extraordinary items) (of Rs. 5/- each) (not annualised*) (a) Basic (Rs.) (b) Diluted (Rs.)	(2.27)* (2.27)*	(1.28)* (1.28)*	0.49* 0.48*	30.17 29.82
16.ii	Earnings per share (after extraordinary items) (of Rs. 5/- each) (not annualised*) (a) Basic (Rs.) (b) Diluted (Rs.)	(2.27)* (2.27)*	(1.28)* (1.28)*	0.49* 0.48*	30.17 29.82

PART II Select information for the Quarter Ended June 30, 2015					
	PARTICULARS	3 MONTHS ENDED	3 MONTHS ENDED	3 MONTHS ENDED	YEAR ENDED
		30/06/2015	31/03/2015	30/06/2014	31/03/2015
A)	Particulars of Shareholding				
	Public shareholding				
	- Number of shares	28,075,661	27,943,161	27,871,988	27,943,161
	- Percentage of shareholding	25.48%	25.39%	25.34%	25.39%
	Promoters and Promoter Group Shareholding				
	a) Pledged/ Encumbered				
	- Number of shares	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total share capital of the Company)	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered				
	- Number of shares	81,985,382	81,985,382	81,985,382	81,985,382
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the Company)	74.39%	74.48%	74.53%	74.48%
B)	Investors Complaints	3 MONTHS ENDED 30/06/2015			
	Pending at the beginning of the quarter		Nil		
	Received during the quarter		Nil		
	Disposed of during the quarter		Nil		
	Remaining unresolved at the end of the quarter		Nil		



Notes To Standalone Results :-

- 1) The results were reviewed by the Audit Committee at their meeting held on August 08, 2015 and approved by the Board of Directors at their meeting held on August 10, 2015 and, have been subject to limited review by the Auditors.
- 2) During the quarter, the Company has allotted 132,500 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.
- 3) Figures for the quarter ended March 31, 2015 are the balancing figures between the audited figures in respect of the full financial year and the unaudited reviewed figures up to the third quarter of the relevant financial year.
- 4) Effective April 1, 2015, the Company has exercised option given under paragraph 16A of Accounting Standard for The Effects of Changes in Foreign Exchange Rates (AS 11) prescribed under Section 133 of the Companies Act, 2013 whereby exchange differences arising on long term foreign currency monetary items relating to depreciable asset are adjusted in fixed assets and depreciated over the balance life of such assets and in other cases are accumulated in Foreign Currency Monetary Item Translation Difference Account (FCMTDA) to be amortised over balance period of long term asset/liability. The balance outstanding(debit) in FCMTDA as on June 30, 2015 is Rs. 825 lakhs.
- 5) The Company is exclusively into Pharmaceutical business Segment.
- 6) Pursuant to the amalgamation of Wockhardt Biopharm Limited and Vinton Healthcare Limited with the Company w.e.f. April 01, 2014, which was accounted for during the quarter ended March 31, 2015, the figures of current quarter are strictly not comparable with the figures for quarters ended March 31, 2015 and June 30, 2014.
- 7) Previous period figures have been recast/ re-grouped to conform to the current period's presentation.



FOR WOCKHARDT LIMITED

[Handwritten Signature]
 H F KHORAKIWALA
 CHAIRMAN

Vitznau, Switzerland
 Date : August 10, 2015